De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Abbott Laboratories Beheer

Beheer criteriumcontroles 3/4

De CEO Abbott Laboratories' is Robert Ford, benoemd in Oct2018, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 23.27M, bestaande uit 6.4% salaris en 93.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.024% van de aandelen van het bedrijf, ter waarde ARS 46.15B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 5.7 jaar.

Belangrijke informatie

Robert Ford

Algemeen directeur

US$23.3m

Totale compensatie

Percentage CEO-salaris	6.4%
Dienstverband CEO	6yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Robert Ford's beloning veranderd ten opzichte van Abbott Laboratories's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Compensatie versus markt: De totale vergoeding ($USD 23.27M ) Robert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de AR markt ($USD 5.68M ).

Compensatie versus inkomsten: De vergoeding van Robert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Robert Ford (50 yo)

6yrs

Tenure

US$23,268,171

Compensatie

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Ford	Chairman of the Board	6yrs	US$23.27m	0.024% ARS 48.3b
Philip Boudreau	CFO & Executive VP of Finance	1.1yrs	US$3.32m	0.0023% ARS 4.5b
Hubert Allen	Executive VP	11.8yrs	US$7.42m	0.011% ARS 21.4b
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10.1yrs	US$5.93m	0.0072% ARS 14.5b
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.8yrs	US$5.50m	0.0035% ARS 7.1b
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	geen gegevens	geen gegevens
Michael Comilla	Vice President of Investor Relations.	no data	geen gegevens	geen gegevens
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	geen gegevens	geen gegevens
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	geen gegevens	geen gegevens
Christopher Scoggins	Senior Vice President of Commercial Operations	1.8yrs	geen gegevens	geen gegevens
Mary Moreland	Executive Vice President of Human Resources	5.2yrs	geen gegevens	0.0059% ARS 11.9b
Jared Watkin	Executive Vice President of Diabetes Care	9.3yrs	geen gegevens	0.0041% ARS 8.3b

5.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ABT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Ford	Chairman of the Board	4.9yrs	US$23.27m	0.024% ARS 48.3b
Daniel Starks	Independent Director	7.7yrs	US$349.29k	0.39% ARS 775.9b
John Stratton	Independent Director	7.8yrs	US$341.96k	0.00020% ARS 402.4m
Nancy McKinstry	Lead Independent Director	12.8yrs	US$405.96k	0.00027% ARS 543.2m
Michael Roman	Independent Director	3.5yrs	US$337.96k	0% ARS 0
Robert Alpern	Independent Director	16yrs	US$441.44k	0% ARS 0
Michael O'Grady	Independent Director	1.5yrs	US$283.96k	0% ARS 0
Michelle Kumbier	Independent Director	6.3yrs	US$331.96k	0.00018% ARS 362.1m
Sally Blount	Independent Director	12.8yrs	US$362.60k	0.00015% ARS 301.8m
Claire Babineaux-Fontenot	Independent Director	2.1yrs	US$354.96k	0% ARS 0
Darren McDew	Independent Director	5.1yrs	US$331.19k	0% ARS 0
Patricia Gonzalez	Independent Director	3.2yrs	US$356.96k	0% ARS 0

5.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).

Abbott Laboratories Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Recent updates

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q2, 2023 Results on Jul 20, 2023

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Declares Quarterly Common Cash Dividend, Payable on August 15, 2023

Abbott Receives FDA Approval for Tactiflex Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott Receives FDA Clearance for Assert-IQ™? Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

Abbott Declares Quarterly Dividend, Payable on May 15, 2023

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Proclaim™ XR

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott and Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Abbott Laboratories to Report Q4, 2022 Results on Jan 25, 2023

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Abbott Laboratories Launches the Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd